The effect of intravenous golimumab on health-related quality of life in rheumatoid arthritis: 24-week results of the phase III GO-FURTHER trial.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

To evaluate the effects of intravenous (IV) golimumab 2 mg/kg + methotrexate (MTX) on patient-reported measures of health-related quality of life (HRQOL) in patients with active rheumatoid arthritis (RA) despite prior MTX therapy.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): J. Rheumatol.

Title: The Journal of rheumatology

Publisher: The Journal of Rheumatology

ISSN: 0315-162X

ISSN (Print): 0315-162X

Publication date (Electronic): Jun 2014

Volume: 41

Issue: 6

Affiliations

[1 ] From the Division of Rheumatology and Allergy and Clinical Immunology, Johns Hopkins University, Baltimore, Maryland; Department of Clinical Rheumatology, Brigham and Women's Hospital, Boston, Massachusetts; Patient Reported Outcomes, Janssen Global Services LLC, Malvern, Pennsylvania; Biostatistics and Immunology, Janssen Research & Development LLC, Spring House, Pennsylvania, USA; Department of Rheumatology, UZ Gasthuisberg, KU Leuven, Belgium.C.O. Bingham III, MD, Division of Rheumatology and Allergy and Clinical Immunology, Johns Hopkins University; M. Weinblatt, MD, Department of Clinical Rheumatology, Brigham and Women's Hospital; C. Han, PhD; T.A. Gathany, PhD, Patient Reported Outcomes, Janssen Global Services; L. Kim, PhD; K.H. Lo, PhD, Biostatistics, Janssen Research & Development LLC; D. Baker, MD; A. Mendelsohn, MD, Immunology, Janssen Research & Development LLC; R. Westhovens, MD, Department of Rheumatology, University Hospitals Leuven; Department of Development and Regeneration, KU Leuven. cbingha2@jhmi.edu.

[2 ] From the Division of Rheumatology and Allergy and Clinical Immunology, Johns Hopkins University, Baltimore, Maryland; Department of Clinical Rheumatology, Brigham and Women's Hospital, Boston, Massachusetts; Patient Reported Outcomes, Janssen Global Services LLC, Malvern, Pennsylvania; Biostatistics and Immunology, Janssen Research & Development LLC, Spring House, Pennsylvania, USA; Department of Rheumatology, UZ Gasthuisberg, KU Leuven, Belgium.C.O. Bingham III, MD, Division of Rheumatology and Allergy and Clinical Immunology, Johns Hopkins University; M. Weinblatt, MD, Department of Clinical Rheumatology, Brigham and Women's Hospital; C. Han, PhD; T.A. Gathany, PhD, Patient Reported Outcomes, Janssen Global Services; L. Kim, PhD; K.H. Lo, PhD, Biostatistics, Janssen Research & Development LLC; D. Baker, MD; A. Mendelsohn, MD, Immunology, Janssen Research & Development LLC; R. Westhovens, MD, Department of Rheumatology, University Hospitals Leuven; Department of Development and Regeneration, KU Leuven.

Article

Publisher Item ID: jrheum.130864

DOI: 10.3899/jrheum.130864

PubMed ID: 24786931

SO-VID: 7afa6568-3e8f-426f-9ad5-3b5afdf96063

History

Keywords: ANTI-TUMOR NECROSIS FACTOR,FATIGUE,PHYSICAL FUNCTION,QUALITY OF LIFE,RHEUMATOID ARTHRITIS

Data availability:

Keywords: ANTI-TUMOR NECROSIS FACTOR, FATIGUE, PHYSICAL FUNCTION, QUALITY OF LIFE, RHEUMATOID ARTHRITIS

The effect of intravenous golimumab on health-related quality of life in rheumatoid arthritis: 24-week results of the phase III GO-FURTHER trial.

Read this article at

Abstract

Related collections

Asian Journal of Quality of Life (AjQoL)

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Similar content 78

Cited by 8